FIELD: pharmacology.
SUBSTANCE: conjugate contains a polylysine dendrimer of G2-G10 generation conjugated to the nitroimidazole ligand-metal complex having the following structure:
,
where n is 0; R1, R2 and R3 are independently H or NO2; R'1 and R'2 are independently H; X1, X2 and X3 are independently CO or H2O, as allowed by the valency of the metal M; and M is a radioactive or non-radioactive ("cold") isotope of a transition metal selected from Y, Mo, Tc, Ru, Pd, Re, In. The pharmaceutical composition is also proposed.
EFFECT: dendrimeric conjugates can be used in detection and treatment of various cancers.
15 cl, 7 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER | 2019 |
|
RU2825637C2 |
| RADIOLABELED PROGASTRIN IN CANCER DIAGNOSIS | 2018 |
|
RU2811734C2 |
| GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
| PARAMINOHYPURIC ACID (PAH) AS A KIDNEY PROTECTOR | 2020 |
|
RU2804349C2 |
| RADIOPHARMACEUTICALS TARGETING GRPR AND THEIR USE | 2019 |
|
RU2798978C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
| COMPOUND FOR DIAGNOSING TUMOURS EXPRESSING PSMA AND COMPOSITION BASED THEREON | 2019 |
|
RU2730507C1 |
| VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | 2010 |
|
RU2600798C2 |
| DIAGNOSTIC COMPOUNDS | 2005 |
|
RU2396272C9 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822091C2 |
